acyclovir, 500 mg/m 2 three times a day given 5 days before until 30 days after transplant was shown to significantly reduce the risk of CMV infection, disease and pneumonia Recipients of HLA-matched, related or unrelated allogeneic BMT who were CMV seropositive or those at 100 days after transplant when compared to no treatment. 2 In a randomised, controlled-study, we confirmed that receiving unmanipulated marrow from a seropositive donor were randomised to receive one of three treathigh-dose intravenous acyclovir reduced the risk of CMV infection 7 months after transplant when compared to ment regimens, i.v. acyclovir 500 mg/m 2 three times a day from 5 days before transplant to 30 days after recipients of low-dose oral acyclovir administered primarily for HSV prophylaxis. 3 In addition, it was shown that by transplant followed by oral acyclovir 800 mg four times a day for a further 6 months, i.v. acyclovir followed by extending the duration of prophylaxis from 35 days to 7 months post-transplant with (high-dose) oral acyclovir, surplacebo, or 400 mg oral acyclovir four times a day followed by placebo (control). This paper reports the 1 vival at the end of the study was significantly increased. In an attempt to confirm this observation, the more convenyear data on the same cohort of patients which was previously reported. Intravenous acyclovir (IV/PCB) sigtional analysis of 1 year survival has been examined. The results from this analysis are now reported. nificantly reduced the risk of CMV infection when compared to the control group. The frequency of adverse events reported was comparable among the three groups. The mortality rate was significantly reduced by Materials and methods the sequential use of i.v. acyclovir followed by oral acyclovir, resulting in a 19% survival advantage at 1 year Recipients of HLA-matched, related or unrelated bone marrow who were seropositive for CMV or those receiving from transplant.
3
In the last decade, new approaches to some of the compliStatistical analysis was performed on an intent-to-treat cations associated with allogeneic BMT such as microbial basis on data collected from transplant until 1 year postinfection, GVHD and leukaemic relapse have been transplant. The time-to-event analyses were performed developed. An analysis of the International BMT Registry using Cox's proportional hazards model with covariates data showed that among recipients of HLA-identical sibling fitted, model adequacy was checked using Martingale and bone marrow treated for advanced leukaemia, the 2-year Deviance residual plot. Kaplan-Meier plots were produced probability of treatment-related mortality declined from to give survival estimates in each treatment group. The pri-68% in 1980-1981 to 46% in 1988-1989. 1 Allogeneic mary end point for this analysis was survival. Secondary BMT offers a considerable advantage in reducing the risk end points were time to CMV infection, which was defined of leukaemia recurrence but this is offset by the substantial as the isolation of CMV from any body fluids (blood, urine, treatment-related mortality substantially nullifying the throat washing, bronchoalveolar lavage) or tissue, CMV benefit over conventional chemotherapy.
disease, HSV disease and VZV disease. CMV pneumonia is one of the main causes of death after allogeneic BMT. If untreated, the mortality rate in patients with CMV pneumonia may be as high as 80%. Intravenous Results
Three hundred and ten patients were recruited from 18 Eur- of the recruited patients have previously been reported. 1 In (four), leukaemia (four), cardiomyopathy and idiopathic pneumonitis (one), and graft rejection (one). All causes of brief, the mean age was 31.2 years in group A, 30.5 years in group B and 30.2 years in group C. A small number of death from the time of transplant until 1 year post-transplant are given in Table 3 . patients less than 10 years of age were entered, six in group A, four in group B and five in group C. These patients were
There was a statistically significant difference between groups A (IV/ACV) and C (ORAL/PCB) in survival time included in the analysis of patients more than 10 years of age. The majority of patients in all treatment groups had (P = 0.01); but no statistically significant difference was found between groups A (IV/ACV) and B (IV/PCB) acute leukaemia (59% in group A, 60% in group B and 55% in group C) and were mostly CMV seropositive (83% (P Ͼ 0.05) nor between groups B (IV/PCB) and C ( Figure 1 ). in group A, 92% in group B and 87% in group C). Chronic myeloid leukaemia was the second most common underlying disease and accounted for 25% of the patients in each
Secondary end points of the three treatment groups.
CMV infection and disease: The Kaplan-Meier estimates of the proportion of patients with CMV infection at the end Primary end points of 360 days post-transplant were 54% in group A (IV/ACV), 50% in group B (IV/PCB), and 60% in group Survival: Female patients and those Ͻ30 years of age were less likely to die within the first year after transplant C (ORAL/PCB). The difference between groups B (IV/PCB) and C (ORAL/PCB) was statistically significant ( Table 2 ). The effect of the donor gender on survival was not studied. The CMV serological status of the recipient (P = 0.03). The difference between groups A (IV/ACV) and C (ORAL/PCB) did not reach significance at the 5% level and the administration of total body irradiation did not influence patient survival in this selected cohort of patients.
(P = 0.08). No statistically significant difference was found between groups A (IV/ACV) and B (IV/PCB). The median Underlying disease, grouped as acute leukaemia, CML, CLL/lymphoma/myeloma, aplastic anaemia/thalassemia times to CMV infection were 165, 180 and 65 days in groups A, B, and C respectively. and others, did not effect survival rate.
The estimated mortality rate 1 year after transplant was Virologically or histologically confirmed CMV disease was reported in nine patients in group A, 15 patients in 32% in group A (IV/ACV), 43% in group B (IV/PCB) and 51% in group C (ORAL/PCB). Nine patients in group A, group B and 10 patients in group C. CMV pneumonia was reported in seven patients in group A, 11 in group B and 16 in group B and 25 in group C died from infections which were not associated with CMV. Six patients in group A six in group C. CMV disease up to day 210 was previously reported. 2 One patient each in group A and group B died after day 210. The causes of late mortality in this group were CMV hepatitis (one), microbial infection which developed CMV disease after day 210. The patient in group A developed CMV pneumonia on day 315 and the patient were not associated with CMV (three), idiopathic pneumonia (one) and leukaemia (one). Five patients in group B died after day 210 from other microbial infection (two), Table 3 Number of deaths and causes of death veno-occlusive disease and leukaemia (one), leukaemia alone (one) and idiopathic pneumonitis (one). In group C, in group B developed CMV gastrointestinal disease on day The estimated proportions of patients with varicella zoster virus (VZV) disease at the end of 1 year post-transplant 317, both patients survived beyond 1 year after transplant. The hazard ratios comparing the time to CMV disease show were 14% in group A, 15% in group B and 13% in group C. that there are no differences between any two of the three groups. Discussion Other herpes virus disease: The estimated proportions of patients in groups A, B, and C with herpes simplex virus
Results from this study showed that intravenous acyclovir at a dose of 500 mg/m 2 given three times a day from 5 days (HSV) disease were 19, 42 and 38%, respectively, 1 year after transplant. The time to onset of the disease was before transplant to 30 days after transplant followed by placebo for a further 6 months (ie Group B) significantly delayed in group A (IV/ACV) when compared to groups B (95% CI for hazard ratio = 0.17, 0.60) and group C (95% delayed the onset of CMV infection. This confirmed the results reported by Meyers et al. 2 The results also suggest CI for hazard ratio = 0.20, 0.71). There was no indication of any treatment differences over one year between group that the suppression of CMV infection by i.v. acyclovir for 1 month provides an effect that is maintained until 1 year B (IV/PCB) and the control group C (Figure 2 ). after transplant. CMV does not encode its own viral thymi-HSV disease over 1 year post-transplant is lower in the group receiving i.v. and oral acyclovir when compared to dine kinase, but recent studies have shown that intracellular phosphorylation of acyclovir is also mediated by CMV the group receiving low-dose oral acyclovir followed by placebo. The number of deaths due to other microbial infec-UL97 phosphotransferase. 4 Pharmacokinetic studies in BMT recipients showed that 500 mg/m 2 three times a day tion is also lower among recipients of i.v. and oral acyclovir. Lönnqvist et al 7 have shown that acyclovir significantly produces peak plasma acyclovir levels up to 123.0 m, which is within the IC 50 range reported for CMV.
5 Data reduced the incidence of bacteraemia in neutropenic patients, possibly by reducing the incidence of oral lesions from this study and that of Meyers therefore supports a role for acyclovir in the suppression of CMV after BMT.
caused by HSV and therefore the translocation of bacteria across the damaged mucosal barrier. Reduction in bacteraeResults from the present study showed that the administration of i.v. acyclovir from day −5 to day +30 followed mia may have reduced the mortality rate of patients reported in the present study. The possibility that reactiby placebo for 6 months (ie Group B) did not significantly reduce the 1 year mortality rate when compared to lowvation of one or several of the herpes viruses might impact on other parameters of the immune function exists and dose oral acyclovir alone, despite the significant reduction of CMV infection. However, the survival rate among might therefore lead to an increased risk from other infections unrelated to the loss of the mucosal barrier. 8 recipients of sequential i.v. and oral acyclovir was increased by almost 20% when compared to recipients of The results of this study showed that the sequential administration of high-dose i.v. acyclovir followed by oral low-dose oral acyclovir. We have previously reported that the administration of i.v. followed by oral acyclovir sigacyclovir for a total of 7 months significantly improved survival 1 year after transplant. In addition, the risk of nificantly reduced the mortality rate 7 months after transplant. The results of this study show that the survival bene-CMV infection during the first year was also reduced by the administration of high dose i.v. acyclovir from 5 days fit is still evident 1 year after transplant. The exact mechanism of this survival benefit is unclear. Possible before transplant until 30 days after transplant. mechanisms are discussed below.
We previously reported a reduction in CMV viraemia at the end of 7 months post-transplant among recipients of i.v. Acknowledgements and oral acyclovir.
3 As CMV viraemia is a good predictor Results from this study showed that the incidence of
